FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1678946474> ?p ?o ?g. }

• W1678946474 endingPage "1751" @default.
• W1678946474 startingPage "1744" @default.
• W1678946474 abstract "Serum cardiac troponins have been demonstrated to have important clinical implications in patients with hypertrophic cardiomyopathy (HC). However, little is known about their roles in patients with obstructive HC. The aim of this study was to explore the clinical significance and determinants of serum cardiac troponin I (cTnI) in patients with obstructive HC using cardiovascular magnetic resonance imaging. We investigated the relations between serum cTnI levels and clinical, echocardiographic, and cardiovascular magnetic resonance parameters and assessed the determinants of serum cTnI in 149 consecutive patients with obstructive HC. The median level of serum cTnI was 0.019 ng/ml (interquartile range 0.009 to 0.044). CTnI was elevated (≥0.04 ng/ml) in 42 (28%) of the overall cohort. Patients with elevated cTnI had greater maximum wall thickness (p <0.001), larger left ventricular mass index (LVMI, p <0.001), more frequency of left atrium diameter ≥50 mm (p = 0.020), higher plasma values of N-terminal pro-B-type natriuretic peptide (p <0.001), and less hypertension (p = 0.014). Serum cTnI levels were positively correlated with maximum wall thickness (r = 0.444, p <0.001), LVMI (r = 0.556, p <0.001), N-terminal pro-B–type natriuretic peptide (r = 0.305, p <0.001), left ventricular end-diastolic volume index (r = 0.246, p = 0.002), and left ventricular end-systolic volume index (r = 0.272, p = 0.001) but negatively with left ventricular ejection fraction (r = −0.180, p = 0.028). On multivariate analysis, LVMI was independently associated with both elevated cTnI (odds ratio 1.032, p = 0.001) and increasing serum cTnI levels (β = 0.556, p <0.001). In addition, the presence of hypertension was independently related to less likely elevated cTnI (odds ratio 0.307, p = 0.029) and decreasing levels of serum cTnI (β = −0.165, p = 0.015). In conclusion, levels of serum cTnI are elevated in a significant proportion of our patients. Serum cTnI is associated with multiple parameters of disease severity, suggesting its great significance in assessing cardiac remodeling in patients with obstructive HC. Left ventricular hypertrophy, as indicated by LVMI, is the major determinant of serum cTnI levels. Serum cardiac troponins have been demonstrated to have important clinical implications in patients with hypertrophic cardiomyopathy (HC). However, little is known about their roles in patients with obstructive HC. The aim of this study was to explore the clinical significance and determinants of serum cardiac troponin I (cTnI) in patients with obstructive HC using cardiovascular magnetic resonance imaging. We investigated the relations between serum cTnI levels and clinical, echocardiographic, and cardiovascular magnetic resonance parameters and assessed the determinants of serum cTnI in 149 consecutive patients with obstructive HC. The median level of serum cTnI was 0.019 ng/ml (interquartile range 0.009 to 0.044). CTnI was elevated (≥0.04 ng/ml) in 42 (28%) of the overall cohort. Patients with elevated cTnI had greater maximum wall thickness (p <0.001), larger left ventricular mass index (LVMI, p <0.001), more frequency of left atrium diameter ≥50 mm (p = 0.020), higher plasma values of N-terminal pro-B-type natriuretic peptide (p <0.001), and less hypertension (p = 0.014). Serum cTnI levels were positively correlated with maximum wall thickness (r = 0.444, p <0.001), LVMI (r = 0.556, p <0.001), N-terminal pro-B–type natriuretic peptide (r = 0.305, p <0.001), left ventricular end-diastolic volume index (r = 0.246, p = 0.002), and left ventricular end-systolic volume index (r = 0.272, p = 0.001) but negatively with left ventricular ejection fraction (r = −0.180, p = 0.028). On multivariate analysis, LVMI was independently associated with both elevated cTnI (odds ratio 1.032, p = 0.001) and increasing serum cTnI levels (β = 0.556, p <0.001). In addition, the presence of hypertension was independently related to less likely elevated cTnI (odds ratio 0.307, p = 0.029) and decreasing levels of serum cTnI (β = −0.165, p = 0.015). In conclusion, levels of serum cTnI are elevated in a significant proportion of our patients. Serum cTnI is associated with multiple parameters of disease severity, suggesting its great significance in assessing cardiac remodeling in patients with obstructive HC. Left ventricular hypertrophy, as indicated by LVMI, is the major determinant of serum cTnI levels." @default.
• W1678946474 created "2016-06-24" @default.
• W1678946474 creator A5007745739 @default.
• W1678946474 creator A5011135881 @default.
• W1678946474 creator A5014589613 @default.
• W1678946474 creator A5017369508 @default.
• W1678946474 creator A5020949128 @default.
• W1678946474 creator A5025289398 @default.
• W1678946474 creator A5044522072 @default.
• W1678946474 creator A5056357684 @default.
• W1678946474 creator A5063802608 @default.
• W1678946474 date "2015-12-01" @default.
• W1678946474 modified "2023-10-14" @default.
• W1678946474 title "Significance and Determinants of Cardiac Troponin I in Patients With Obstructive Hypertrophic Cardiomyopathy" @default.
• W1678946474 cites W109657961 @default.
• W1678946474 cites W157705412 @default.
• W1678946474 cites W1970647693 @default.
• W1678946474 cites W1975579809 @default.
• W1678946474 cites W1996636073 @default.
• W1678946474 cites W2005668504 @default.
• W1678946474 cites W2007372302 @default.
• W1678946474 cites W2016797987 @default.
• W1678946474 cites W2016985382 @default.
• W1678946474 cites W2056559849 @default.
• W1678946474 cites W2063260491 @default.
• W1678946474 cites W2063893017 @default.
• W1678946474 cites W2069939129 @default.
• W1678946474 cites W2082743257 @default.
• W1678946474 cites W2097618980 @default.
• W1678946474 cites W2100039277 @default.
• W1678946474 cites W2109318652 @default.
• W1678946474 cites W2118891131 @default.
• W1678946474 cites W2119361626 @default.
• W1678946474 cites W2144393548 @default.
• W1678946474 cites W26417677 @default.
• W1678946474 cites W4211100568 @default.
• W1678946474 doi "https://doi.org/10.1016/j.amjcard.2015.09.006" @default.
• W1678946474 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26434514" @default.
• W1678946474 hasPublicationYear "2015" @default.
• W1678946474 type Work @default.
• W1678946474 sameAs 1678946474 @default.
• W1678946474 citedByCount "16" @default.
• W1678946474 countsByYear W16789464742016 @default.
• W1678946474 countsByYear W16789464742017 @default.
• W1678946474 countsByYear W16789464742020 @default.
• W1678946474 countsByYear W16789464742021 @default.
• W1678946474 countsByYear W16789464742022 @default.
• W1678946474 crossrefType "journal-article" @default.
• W1678946474 hasAuthorship W1678946474A5007745739 @default.
• W1678946474 hasAuthorship W1678946474A5011135881 @default.
• W1678946474 hasAuthorship W1678946474A5014589613 @default.
• W1678946474 hasAuthorship W1678946474A5017369508 @default.
• W1678946474 hasAuthorship W1678946474A5020949128 @default.
• W1678946474 hasAuthorship W1678946474A5025289398 @default.
• W1678946474 hasAuthorship W1678946474A5044522072 @default.
• W1678946474 hasAuthorship W1678946474A5056357684 @default.
• W1678946474 hasAuthorship W1678946474A5063802608 @default.
• W1678946474 hasConcept C115725540 @default.
• W1678946474 hasConcept C119060515 @default.
• W1678946474 hasConcept C126322002 @default.
• W1678946474 hasConcept C126838900 @default.
• W1678946474 hasConcept C143409427 @default.
• W1678946474 hasConcept C164705383 @default.
• W1678946474 hasConcept C2775915353 @default.
• W1678946474 hasConcept C2776008845 @default.
• W1678946474 hasConcept C2778198053 @default.
• W1678946474 hasConcept C2780185194 @default.
• W1678946474 hasConcept C36036425 @default.
• W1678946474 hasConcept C500558357 @default.
• W1678946474 hasConcept C63363279 @default.
• W1678946474 hasConcept C71924100 @default.
• W1678946474 hasConcept C78085059 @default.
• W1678946474 hasConceptScore W1678946474C115725540 @default.
• W1678946474 hasConceptScore W1678946474C119060515 @default.
• W1678946474 hasConceptScore W1678946474C126322002 @default.
• W1678946474 hasConceptScore W1678946474C126838900 @default.
• W1678946474 hasConceptScore W1678946474C143409427 @default.
• W1678946474 hasConceptScore W1678946474C164705383 @default.
• W1678946474 hasConceptScore W1678946474C2775915353 @default.
• W1678946474 hasConceptScore W1678946474C2776008845 @default.
• W1678946474 hasConceptScore W1678946474C2778198053 @default.
• W1678946474 hasConceptScore W1678946474C2780185194 @default.
• W1678946474 hasConceptScore W1678946474C36036425 @default.
• W1678946474 hasConceptScore W1678946474C500558357 @default.
• W1678946474 hasConceptScore W1678946474C63363279 @default.
• W1678946474 hasConceptScore W1678946474C71924100 @default.
• W1678946474 hasConceptScore W1678946474C78085059 @default.
• W1678946474 hasIssue "11" @default.
• W1678946474 hasLocation W16789464741 @default.
• W1678946474 hasLocation W16789464742 @default.
• W1678946474 hasOpenAccess W1678946474 @default.
• W1678946474 hasPrimaryLocation W16789464741 @default.
• W1678946474 hasRelatedWork W1504596276 @default.
• W1678946474 hasRelatedWork W2021479488 @default.
• W1678946474 hasRelatedWork W2051712573 @default.
• W1678946474 hasRelatedWork W2328354663 @default.
• W1678946474 hasRelatedWork W2365641182 @default.
• W1678946474 hasRelatedWork W2368256042 @default.

• next